Drugs / Allo-hMSCs
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03058068 | Dec 2020 → Sep 2027 | cystic fibrosis | Joshua M Hare | Withdrawn | No outcome recorded |
| Phase 1 | NCT02675556 | Oct 2017 → Mar 2019 | — | Joshua M Hare | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02398604 | Apr 2015 → Mar 2019 | hypoplastic left heart syndrome | Longeveron Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01087996 | Mar 2010 → Apr 2011 | disease related to hematopoietic stem cell transplant | University of Miami | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allo-hMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03058068 ↗ |
| Known as | Allogeneic human mesenchymal stem cells | “Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs)” NCT01087996 ↗ |
| Modality | Cell therapy | “Allogeneic human mesenchymal stem cells” NCT01087996 ↗ |
| Route | Other | “The injections will be administered transendocardially during cardiac catheterization” NCT01087996 ↗ |